retifanlimab,pembrolizumab,Bria-IMT
Incyte,Merck,BriaCell Therapeutics
['bria-imt']
carmen calfa, m.d., of , associate professor of clinical medicine, principle clinical investigator, and co-author of the study of bria-imt combination regimen comments on positive data presented at the 2023 . #aacr2023 $bctx $bctxw 
An immuno-oncology company developing targeted and effective immunotherapies for advanced breast cancer and other cancers. (Nasdaq: $BCTX, $BCTXW) (TSX: BCT)